Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Something big is likely in the works

<< Previous

Bullboard Posts

Next >>

Comment by jfm1330on Jan 07, 2022 10:53am

163 Views

Post# 34292810

RE:RE:Something big is likely in the works

Funny to read that. All those complaints on how bad this company is at almost everything, but don't sell my wealth!!!

realitycheck4u wrote:
They had better not sell the company or I would be the first in line to look at all my options on Board members not managing the company for all shareholders interest. If they did that, it would only be golden parachutes and I would not accept that. We have invested because we want them to lead us to a product launch and to enjoy that ride - not a fire sale. I suspect we could russel up support from all of us and from the new investors. We want to see success here, and not by some other company enjoying all the upside. THTX has $100++ potential. They had better not sell. I would rather go to zero and have Sort+ fail than see it sold for $20 or even 50.

SPCEO1 wrote: Evidence:

1.) They managed to get the retired Pfizer CMO as a scientific consutant

2.) They liked their IR officer but she left because a family situation would not allow her to travel - so they needed someone in that role who could travel and explain what is going to be announced.

3.) They have gone totally silent yet still have meetings scheduled with large shareholders later this month.

4.) They pulled the corporate presentation and have not yet replaced it. It would be pretty easy to update if there was not something significant going on that would really lead to material changes.

5.) They gave larger options grants and gave them earlier than normal.

My best guess is whatever is coming down the pike will be viewed as a positive development. The chances of a big fundraising occurring on the back of any such good news is high, unless the good news is partnership agreements that bring upfront cash along with them.

There could be a series of pieces of good news - China cancer partnership, other cancer partnerships, NASH partnership, acquisition of other drugs, selling Trogarzo rights to someone else to concentrate on Egrifta and cancer, etc.

There could also be a friendly acquisition of THTX in play and that is why things have gone silent and big options grants, etc.

While the market is tired of the wait for news, there is meaningful evidence that something signifcant and good is being worked on behind the scenes.